Back to top

Beam Therapeutics initiated with a Buy at Jefferies

Jefferies initiated coverage of Beam Therapeutics (BEAM) with a Buy rating and $41 price target The firm, which believes BEAM-302 for Alpha-1 Antit...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Beam Therapeutics Inc. (BEAM)